GlassScriptPhysician profile
Suzanne Melville Marshall
NPI 1053696468
$4,746.12
in general payments reported to CMS, 2019-2025
34 companies · $726 in 2025
The $726 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $863 · 2022: $1,119 · 2023: $1,080 · 2024: $957 · 2025: $726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,679 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,678.95 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,148.61 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $1,019.93 | 2021-2025 | |
| Dexcom, INC. | $307.17 | 2021-2024 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Glaxosmithkline, LLC. | $216.47 | 2021-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $186.67 | 2021-2024 | Jardiance |
| Pfizer INC. | $177.64 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $177.46 | 2021-2025 | |
| Lilly USA, LLC | $171.57 | 2022-2024 | Jardiance, Mounjaro, Emgality |
| Janssen Pharmaceuticals, INC | $162.71 | 2021-2022 | |
| Astellas Pharma US INC | $159.62 | 2022-2025 | Veozah |
| Amarin Pharma, INC. | $109.58 | 2021-2022 | |
| Esperion Therapeutics, INC. | $100.65 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $95.38 | 2021-2022 | |
| Amgen INC. | $77.16 | 2024-2025 | Otezla, Repatha, Otezla |
| Phathom Pharmaceuticals, INC. | $70.43 | 2024-2025 | Voquezna |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $63.81 | 2022 | |
| Merck Sharp & Dohme LLC | $58.89 | 2021-2024 | Gardasil 9, Gardasil, Capvaxive |
| Abbott Laboratories | $44.00 | 2022-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $41.24 | 2022-2024 | Enhertu |
| Kowa Pharmaceuticals America, INC. | $41.04 | 2021-2025 | Zoryve |
| Genentech USA, INC. | $40.86 | 2021 | |
| Azurity Pharmaceuticals, INC. | $36.05 | 2024-2025 | Azmiro, Horizant |
| Coloplast Corp | $29.56 | 2021 | |
| Novartis Pharmaceuticals Corporation | $28.82 | 2021-2022 | |
| Si-Bone, INC. | $25.92 | 2025 | |
| Heartflow, INC. | $23.43 | 2023 | Ffrct |
| Nestle Healthcare Nutrition INC. | $20.30 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $17.35 | 2024 | Crysvita |
| Axsome Therapeutics, INC. | $16.79 | 2024 | Auvelity |
| Aimmune Therapeutics, INC. | $16.16 | 2024 | |
| Nevro Corp. | $15.83 | 2023 | Senza |
| Acella Pharmaceuticals, LLC | $15.45 | 2025 | NP Thyroid 60 |
| Eisai INC. | $15.43 | 2021 | |
| Halozyme INC | $14.14 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Marshall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.